<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02351180</url>
  </required_header>
  <id_info>
    <org_study_id>WUIBCARV1-201404080</org_study_id>
    <nct_id>NCT02351180</nct_id>
  </id_info>
  <brief_title>Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients</brief_title>
  <official_title>A Randomized Placebo Controlled Trial of Inhaled Beclomethasone After Community-acquired Respiratory Viral Infection in Lung Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of inhaled beclomethasone after a&#xD;
      community-acquired respiratory viral infection in a lung transplant recipient decreases the&#xD;
      risk of the subsequent development of chronic lung allograft dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Community-acquired respiratory viral (CARV) infections after lung transplantation are&#xD;
      associated with an increased risk for the development of chronic lung allograft dysfunction&#xD;
      (CLAD) after lung transplantation. The exact mechanisms whereby CARV infections increase this&#xD;
      risk are unknown. We propose that viral infection results in airway epithelial cell injury&#xD;
      and the expression of injury-response genes that provide signals that initiate immunologic&#xD;
      and non-immunologic pathways that result in the airway remodeling characteristic of&#xD;
      obliterative bronchiolitis, the predominant pathology of CLAD. Systemic and inhaled&#xD;
      corticosteroids are frequently used as anti-inflammatory agents to treat the peribronchiolar&#xD;
      inflammation seen in viral bronchiolitis. Beneficial effects from corticosteroids have been&#xD;
      reported, but this has not been demonstrated in lung transplant recipients. The aim of this&#xD;
      single center, randomized, double blind, placebo controlled study is to evaluate the short&#xD;
      and long term effects of a 6 month course of inhaled beclomethasone on adult lung transplant&#xD;
      recipients with CARV infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from new or progressive chronic lung allograft dysfunction</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory virus symptom score</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute rejection</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytic bronchiolitis</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor-specific antibodies</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic lung allograft dysfunction</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Lung Transplant Infection</condition>
  <arm_group>
    <arm_group_label>Inhaled beclomethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled beclomethasone 320 mcg twice daily for 180 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled placebo twice daily for 180 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled beclomethasone</intervention_name>
    <description>Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection</description>
    <arm_group_label>Inhaled beclomethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will serve as a control treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (â‰¥ 18 years old)&#xD;
&#xD;
          -  Single, bilateral, or heart-lung transplant recipient&#xD;
&#xD;
          -  Confirmed infection with a community-acquired respiratory virus including: adenovirus,&#xD;
             coronavirus, influenza A or B, respiratory syncytial virus (RSV), parainfluenza virus&#xD;
             (PiV), human metapneumovirus (hMPV), and rhinovirus&#xD;
&#xD;
          -  At least 6 months post-transplant, with completion of 6 month bronchoscopy if&#xD;
             indicated&#xD;
&#xD;
          -  Able and willing to give written informed consent and comply with study procedures&#xD;
             (e.g. testing, treatment)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BOS Stage 3&#xD;
&#xD;
          -  Requirement for mechanical ventilation at study entry&#xD;
&#xD;
          -  Use of inhaled steroids at the time of CARV infection&#xD;
&#xD;
          -  Any condition that in the investigator's opinion would preclude the patient's&#xD;
             participation in a clinical trial&#xD;
&#xD;
          -  Lack of available spirometric data to establish a baseline forced expiratory volume in&#xD;
             1 second and/or forced vital capacity&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Current participation in another interventional clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramsey Hachem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>January 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2015</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic lung allograft dysfunction</keyword>
  <keyword>Community-acquired respiratory viral infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

